样式: 排序: IF: - GO 导出 标记为已读
-
Small Bowel Bleeding Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-12 Daniel Wild, Cynthia Ko
-
Clinical Updates in Colon Endoscopic Mucosal Resection Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-10 Mohammad Bilal, Heiko Pohl
-
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-05 Mohammad Shehab, Fatema Alrashed, Abdulwahab Alsayegh, Usama Aldallal, Christopher Ma, Neeraj Narula, Vipul Jairath, Siddharth Singh, Talat Bessissow
Treatment options for moderate to severe ulcerative colitis (UC) are increasing rapidly, but the lack of comparative efficacy trials makes treatment choices a clinical challenge. This network-meta-analysis aimed to compare the relative efficacy of biologics and small molecules in achieving remission in patients with moderate to severe UC.
-
The Association Between Obesity and Malignant Progression of Barrett’s Esophagus: A Systematic Review and Dose-Response Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-03 Mie Thu Ko, Tom Thomas, Emily Holden, Ian L.P. Beales, Leo Alexandre
Obesity is a risk factor for both Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). However, it is unclear whether obesity drives the malignant progression of BE. We aimed to assess whether obesity is associated with high-grade dysplasia (HGD) or cancer in patients with BE.
-
Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Siddharth Singh, Gry Juul Poulsen, Tania Hviid Bisgaard, Linéa Bonfils, Tine Jess
We examined the incidence and natural history of patients with very elderly onset (herein referred to as very late-onset) inflammatory bowel diseases (IBDs) (≥ 70 years of age at diagnosis), compared with patients diagnosed between 60 and 69 years of age in Denmark.
-
Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Laura Turco, Madalina-Gabriela Taru, Giovanni Vitale, Horia Stefanescu, Federica Mirici Cappa, Sonia Berardi, Anna Baldan, Roberto Di Donato, Paolo Pianta, Vittoria Vero, Luca Vizioli, Lucia Maria Procopciuc, Bogdan Procopet, Maria Cristina Morelli, Fabio Piscaglia
Nonselective beta-blockers (NSBBs) can lower the risk of first decompensation in patients with cirrhosis and clinically significant portal hypertension (CSPH) (identified by a hepatic venous pressure gradient ≥10 mm Hg) with active etiology. Our aim was to examine the effect of NSBBs on first decompensation occurrence in patients with cirrhosis and enduring CSPH after etiological treatment.
-
Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Mohammad Zamani, Shaghayegh Alizadeh-Tabari, Veeral Ajmera, Siddharth Singh, Mohammad Hassan Murad, Rohit Loomba
Limited data exist regarding the estimate of the prevalence of advanced liver fibrosis and cirrhosis in the general population. Therefore, we conducted a systematic review and meta-analysis to evaluate the global prevalence and risk factors of advanced fibrosis and cirrhosis.
-
Alcohol Rehabilitation Within 3 Months After Alcohol Hepatitis and Survival - A National Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Lucia Parlati, Charlotte Mouliade, Eric Nguyen Khac, Mathis Collier, Stylianos Tzedakis, Samir Bouam, Anoisia Courtois, Marion Corouge, Alexandre Louvet, Stanislas Pol, Philippe Sogni, Amine Benyamina, Jürgen Rehm, Philippe Mathurin, Vincent Mallet, Demosthenes research group
There is limited understanding of the benefits of alcohol rehabilitation after alcohol hepatitis (AH).
-
Biopsy Proteome Score Performs Well as an Effect Measure in a Gluten Challenge Trial of Celiac Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Anette Johansen, Geir Kjetil F. Sandve, Joseph R. Maxwell, Glennda Smithson, Ludvig M. Sollid, Jorunn Stamnaes
Development of novel treatments for celiac disease is dependent on precise tools to monitor changes in gluten-induced mucosal damage. Current histology measures are subjective and difficult to standardize. Biopsy proteome scoring is an objective alternative to histology which is based on robust changes in biological pathways that directly reflect gluten-induced mucosal damage. In this study, we aimed
-
High Diagnostic Value of Transient Elastography for Advanced Fibrosis and Cirrhosis in Patients With Chronic Hepatitis Delta Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Dominique Roulot, Ségolène Brichler, Richard Layese, Louis D’alteroche, Nathalie Ganne-Carrie, Christiane Stern, Antonio Saviano, Vincent Leroy, Françoise Roudot-Thoraval, Victor De Ledinghen, DELTAVIR study group, Véronique Loustaud-Ratti, Christine Silvain, Souad Benali, Patrick Ingiliz, Martial Gouton, Dominique Guyader, Bruno Roche, Olivier Chazouillères, Tarik Asselah, Marianne Ziol
Liver biopsy remains the gold standard for fibrosis staging in patients with chronic hepatitis delta (CHD). Here, we comparatively evaluated the performance of transient elastography (TE) and biomarkers for the diagnosis of liver fibrosis in patients with CHD.
-
Accuracy of Computer-aided Diagnosis in Colonoscopy Varies According to Polyp Location: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Tommy Rizkala, Cesare Hassan, Yuichi Mori, Marco Spadaccini, Giulio Antonelli, Evelien Dekker, Britt B.S.L. Houwen, Oliver Pech, Sebastian Baumer, Emanuele Rondonotti, Franco Radaelli, James Weiquan Li, Daniel von Renteln, Masashi Misawa, Antonio Facciorusso, Roberta Maselli, Silvia Carrara, Alessandro Fugazza, Antonio Capogreco, Kareem Khalaf, Harsh Patel, Prateek Sharma, Douglas Rex, Alessandro Repici
Computer-aided diagnosis (CADx) assists endoscopists in differentiating between neoplastic and non-neoplastic polyps during colonoscopy. This study aimed to evaluate the impact of polyp location (proximal vs. distal colon) on the diagnostic performance of CADx for ≤5 mm polyps.
-
Missed Opportunity to Triage Patients With Irritable Bowel Syndrome to Multidisciplinary Therapy Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Bhavana Tetali, William D. Chey, Stacy B. Menees
-
Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn’s Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Joana Revés, Agnes Fernandez-Clotet, Ingrid Ordás, Anthony Buisson, Maëva Bazoge, Constance Hordonneau, Pierre Ellul, Melvin D’Anastasi, Ainara Elorza, Marta Aduna, Iago Rodríguez-Lago, Inês Sousa Lajas, Ana Raimundo, Paulo J.G. Bettencourt, Gonçalo Freire, Pedro Sousa, Ana Primitivo, Ivo Delgado, Jordi Rimola, Joana Torres
Transmural healing (TH) is emerging as a potential Crohn's disease (CD) treatment target. Early biological treatment seems to be associated with improved disease outcomes, but its impact on TH remains unclear. We aimed to assess the impact of early biological treatment initiation on TH and its influence on CD prognosis.
-
Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Ryma Terbah, Anoop N. Koshy, Avik Majumdar, Karl Vaz, Adam Testro, Marie Sinclair
Cardiac dysfunction is a key factor in the pathogenesis of hepatorenal syndrome, for which terlipressin is the recommended first-line treatment. This study investigates whether long-term terlipressin can ameliorate the subclinical cardiac dysfunction observed in decompensated cirrhosis.
-
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Dennis Yang, Abdul Mohammed, Rena Yadlapati, Andrew Y. Wang, Thurarshen Jeyalingam, Peter V. Draganov, Ernesto Robalino Gonzaga, Muhammad K. Hasan, Alexander Schlachterman, Ming-Ming Xu, Ahmed Saeed, Aziz Aadam, Reem Z. Sharaiha, Ryan Law, Louis M. Wong Kee Song, Monica Saumoy, John E. Pandolfino, Makoto Nishimura, Michel Kahaleh, Joo Ha Hwang, Robert Bechara, Vani JA. Konda, John M. DeWitt, Prashant
There is significant variability in the immediate post-operative and long-term management of patients undergoing per-oral endoscopic myotomy (POEM), largely stemming from the lack of high-quality evidence. We aimed to establish a consensus on several important questions on the after care of post-POEM patients through a modified Delphi process.
-
Predictors of Functional Cure of Chronic Hepatitis B Virus Infection: A Long-Term Follow-Up Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Jia-Feng Wu, Chi-San Tai, Kai-Chi Chang, Yuh-Jue Chen, Chien-Ting Hsu, Huey-Ling Chen, Yen-Hsuan Ni, Mei-Hwei Chang
A functional cure is an essential endpoint in the management of patients with chronic hepatitis B virus (HBV) infection. We evaluated the cumulative probability and predictors of functional cure in patients with chronic HBV infection after hepatitis B e antigen (HBeAg) seroconversion.
-
Thiopurines and the Risk of Cancer in Patients With Inflammatory Bowel Disease and Reference Individuals Without Inflammatory Bowel Disease – A Danish Nationwide Cohort Study (1996-2018) Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Mads Damsgaard Wewer, Gasper Letnar, Klaus Kaae Andersen, Mikkel Malham, Vibeke Wewer, Jakob Benedict Seidelin, Flemming Bendtsen, Johan Burisch
Thiopurine therapy is a cornerstone in the treatment of inflammatory bowel disease (IBD). We aimed to assess the effect of thiopurines on cancer risk in IBD according to drug exposure and age.
-
Reliability of Intestinal Ultrasound for Evaluating Crohn’s Disease Activity Using Point-of-care and Central Reading Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Thomas M. Goodsall, Yoon-Kyo An, Jane M. Andrews, Jakob Begun, Antony B. Friedman, Andrew Lee, Peter J. Lewindon, Paul Spizzo, Nick Rodgers, Kirstin M. Taylor, Lauren S. White, Rune Wilkens, Emily K. Wright, Lily Zou, Bryan R. Maguire, Claire E. Parker, Julie Rémillard, Kerri L. Novak, Remo Panaccione, Brian G. Feagan, Vipul Jairath, Christopher Ma, Robert V. Bryant
Intestinal ultrasound (IUS) is increasingly used to assess Crohn’s disease (CD) activity in clinical practice. However, application in clinical trials has been limited by heterogeneous scoring methods and concerns about reliability. We aimed to determine the inter- and intra-rater reliability of locally and centrally read IUS parameters for evaluating CD using prospectively performed scans.
-
Validation of a National Pathology Database for Colonoscopy Quality Reporting and Assurance Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Andrew J. Gawron, Grace Mckee, Jason A. Dominitz, Yiwen Yao, Mary Whooley, Tonya Kaltenbach
-
Racial, Ethnic, and Geographic Disparities in Digestive Diseases Mortality in the United States, 2000–2019 Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Wafa A. Aldhaleei, Michael B. Wallace, Yan Bi, Ann M. Rusk, Akshaya Srikanth Bhagavathula
The global burden of digestive diseases mortality has been increasing over the last 3 decades. However, little is known about disparities in digestive diseases–specific mortality in the United States. This study aimed to examine racial, ethnic, and state- and county-level disparities in digestive diseases mortality rate in the United States between 2000 and 2019.
-
Reply on “Tenofovir is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus-related Hepatocellular Carcinoma” Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Kai-Chun Chang, Tung-Hung Su, Jia-Horng Kao
-
Rectal Cavernous Hemangioma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Xi Zhou, Jiaojun Li, Jing Shan
-
Variance Between Clinical Guidance and Real-world Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Mary E. Rinella, Mark L. Hartman, Shraddha Shinde, David Schapiro, Victoria Higgins, Quentin M. Anstee
-
Association of Vibration-controlled Transient Elastography and Clinical Outcomes in Liver Transplant Recipients Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Jian Wang, Tao Fan, Rui Huang
-
Cystic Retroperitoneal Mass Decades in the Making Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Lena Hasson, Clayton Smith, James Michael Mitchell
-
Performance of AI-Enabled Electrocardiogram in the Prediction of Metabolic Dysfunction–Associated Steatotic Liver Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Prowpanga Udompap, Kan Liu, Itzhak Zachi Attia, Rachel E. Canning, Joanne T. Benson, Terry M. Therneau, Peter A. Noseworthy, Paul A. Friedman, Puru Rattan, Joseph C. Ahn, Douglas A. Simonetto, Vijay H. Shah, Patrick S. Kamath, Alina M. Allen
Accessible noninvasive screening tools for metabolic dysfunction–associated steatotic liver disease (MASLD) are needed. We aim to explore the performance of a deep learning–based artificial intelligence (AI) model in distinguishing the presence of MASLD using 12-lead electrocardiogram (ECG).
-
Systematic Review and Meta-analysis: The Three-year Post-colonoscopy Colorectal Cancer Rate as per the World Endoscopy Organization Methodology Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Rawen Kader, Andreas V. Hadjinicolaou, Nicholas E. Burr, Paul Bassett, Omer F. Ahmad, Lasse Pedersen, Manish Chand, Roland Valori, Danail Stoyanov, Laurence B. Lovat
In 2018, the World Endoscopy Organization (WEO) introduced standardized methods for calculating post-colonoscopy colorectal cancer-3yr rates (PCCRC-3yr). This systematic review aimed to calculate the global PCCRC-3yr according to the WEO methodology, its change over time, and to measure the association between risk factors and PCCRC occurrences.
-
Opening a Can of Worms: A Case of Strongyloidiasis Diagnosed by Colonoscopy Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Jamil O. Alexis, Wenyi Luo, Benjamin A. Lerner
-
Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Naomi Uemura, Yoshikazu Kinoshita, Ken Haruma, Ryoji Kushima, Takashi Yao, Junichi Akiyama, Nobuo Aoyama, Yuji Baba, Chihiro Suzuki, Kaori Ishiguro
Acid secretion inhibitors are associated with hypergastrinemia, which can lead to gastric mucosal changes. Potassium-competitive acid blockers, such as vonoprazan, are more potent than proton pump inhibitors, but long-term safety data are lacking.
-
Leveraging Generational Differences in the Gastroenterology Workforce to Promote Satisfaction and a Harmonious Work Environment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Jennifer M. Kolb, Elizabeth Magnan, John M. Carethers, Swati G. Patel
-
Membranous Caval Obliteration and “Showerhead”-like Venous Obstruction in Budd-Chiari Syndrome Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Koichiro Hata, Tsuyoshi Ohno, Etsuro Hatano
-
Emphysematous Hepatitis Due to Clostridiumsepticum Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-24 Amani Al Khatib Amani, Henri Duboc, Heithem Soliman
-
Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Shi Liu, Grace Lai-Hung Wong, Rong Fan, Junqi Niu, Hong Ma, Wanying Liang, Xingyu Lu, Jianping Xie, Jia Shang, Dongying Xie, Yali Liu, Bin Zhou, Qing Xie, Jie Peng, Hongbo Gao, Huiying Rao, Jinjun Chen, Jifang Sheng, Sheng Shen, Song Yang, Xiaoguang Dou, Zhengang Zhang, Vincent Wai-Sun Wong, Jinlin Hou, Jian Sun
Hepatocellular carcinoma (HCC) risk prediction models established in patients with chronic hepatitis B receiving a nucleos(t)ide analogue (NA) rarely include viral factors because of mediocre predictability of traditional viral markers. Here, we investigate the role of serum hepatitis B virus (HBV) RNA, a novel biomarker, in predicting HCC risk in NA-treated patients.
-
Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim
We compared the effects of a 12-week intermittent calorie restriction (ICR) and standard-of-care (SOC) diet on liver fat content (LFC) in metabolic dysfunction–associated steatotic liver disease patients.
-
Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Won-Mook Choi, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, W. Ray Kim, Leland J. Yee, Craig Brooks-Rooney, Tristan Curteis, Laura J. Clark, Zarena Jafry, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang, Young-Joo Jin, Dae Won Jun, Jin-Wook Kim, Neung Hwa Park, Cheng-Yuan Peng, Hyun Phil Shin, Jung Woo Shin, Yao-Hsu Yang, Young-Suk Lim
Hepatocellular carcinoma (HCC) risk persists in patients with chronic hepatitis B (CHB) despite antiviral therapy. The relationship between pre-treatment baseline hepatitis B virus (HBV) viral load and HCC risk during antiviral treatment remains uncertain.
-
Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Stephanie Ioannou, Ashley Beecham, Lissette Gomez, Ryan Dauer, Nidah Khakoo, Lauren Pascual, Maria Quintero, Joanna Lopez, James S. Leavitt, Norma Solis, Mailenys Ortega, Amar R. Deshpande, David H. Kerman, Siobhan Proksell, Esther A. Torres, Talin Haritunians, Dalin Li, Maria T. Abreu, Dermott P.B. McGovern, Jacob L. McCauley, Oriana M. Damas
The prevalence of inflammatory bowel disease among Hispanic/Latine communities is increasing. Pharmacogenomic studies reveal genetic markers that influence treatment decisions. The aim of our study was to examine the frequency and impact of genetic polymorphisms on thiopurine-associated leukopenia (NUDT15, TPMT) and anti-tumor necrosis factor (TNF) immunogenicity (HLA-DQA1∗05) in a cohort of Hispanic
-
Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Jin Ge, Aryana T. Far, Jean C. Digitale, Mark J. Pletcher, Jennifer C. Lai, National COVID Cohort Collaborative (N3C) Consortium, Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin, Anita Walden, Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel
The virulence and severity of SARS-CoV-2 infections have decreased over time in the general population due to vaccinations and improved antiviral treatments. Whether a similar trend has occurred in patients with cirrhosis is unclear. We used the National COVID Cohort Collaborative (N3C) to describe the outcomes over time.
-
Emergency Department Utilization and Outcomes Among Adults With Cirrhosis From 2008 to 2022 in the United States Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Hirsh Elhence, Jennifer L. Dodge, Jennifer A. Flemming, Brian P. Lee
Globally, emergency departments (ED) are experiencing rising costs and crowding. Despite its importance, ED utilization and outcomes among patients with cirrhosis are understudied.
-
Travel Time to Treating Center is Associated With Diagnostic Delay in Pediatric Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Joi F. McLaughlin, Tiffany Linville, Traci W. Jester, Tuvia A. Marciano, Farrah Lazare, Jennifer L. Dotson, Charles Samson, Barbara Niklinska-Schirtz, Jose Cabrera, Ian Leibowtiz, Suruchi Batra, Rana Ammoury, Jennifer A. Strople, Shehzad Saeed, Kelly C. Sandberg, Jeanne Tung, Sofia G. Verstraete, Ryan F. Cox, Sera Na, Steven J. Steiner, Sabina A. Ali, Esther J. Israel, Jill Dorsey, Jeremy Adler, Yuliya
Delayed diagnosis of inflammatory bowel disease (IBD) leads to prolonged symptoms and worse long-term outcomes. We sought to evaluate whether race, ethnicity, disease type, and social factors are associated with delayed diagnosis of pediatric IBD.
-
IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-23 Nikhil Vergis, Vishal Patel, Karolina Bogdanowicz, Justyna Czyzewska-Khan, Rosemary Keshinro, Francesca Fiorentino, Emily Day, Paul Middleton, Stephen Atkinson, Thomas Tranah, Mary Cross, Daphne Babalis, Neil Foster, Emma Lord, Alberto Quaglia, Josephine Lloyd, Robert Goldin, William Rosenberg, Richard Parker, Paul Richardson, Steven Masson, Gavin Whitehouse, Cyril Sieberhagan, David Patch, Nikolai
Short-term mortality in alcohol-related hepatitis (AH) is high, and no current therapy results in durable benefit. A role for interleukin (IL)-1β has been demonstrated in the pathogenesis of alcohol-induced steatohepatitis. This study explored the safety and efficacy of canakinumab (CAN), a monoclonal antibody targeting IL-1β, in the treatment of patients with AH.
-
Prevalence and Incidence of Hepatitis E Infection in China Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-22 Sailimai Man, Jingzhu Fu, Xiaochen Yang, Yuan Ma, Heling Bao, Jing Du, Canqing Yu, Jun Lv, Hui Liu, Gang Li, Bo Wang, Liming Li
China is an endemic area for hepatitis E virus (HEV) infection. Estimating the prevalence and incidence of HEV infection in China plays a pivotal role in informing public health policies to prevent and control hepatitis E. This study aimed to investigate the prevalence of anti-HEV IgG and incidence of HEV seroconversion in China.
-
Endoscopic Findings of a Splenic Vein Stent Eroding Into a Pancreatic Fluid Collection Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-22 Michael A. Perrin, Clark Hair, Shifa Umar
-
Persistence of Lugol-unstaining is Associated With an Increased Risk of Progression to Malignancy in the Esophagus Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-22 Mengfei Liu, Zeyu Yan, Zifan Qi, Ren Zhou, Chuanhai Guo, Anxiang Liu, Haijun Yang, Fenglei Li, Liping Duan, Lin Shen, Qi Wu, Zhen Liu, Yaqi Pan, Ying Liu, Fangfang Liu, Hong Cai, Zhonghu He, Yang Ke
The aim of this study was to investigate the persistence of Lugol-unstained lesions (LULs) in the esophagus detected by chromoendoscopy and explore their association with progression to malignancy.
-
The Cost of Inflammatory Bowel Disease Care – How to Make it Sustainable Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-14 Johan Burisch, Jennifer Claytor, Inmaculada Hernandez, Jason Ken Hou, Gilaad G. Kaplan
The rising global prevalence of inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, underscores the need to examine current and future IBD care costs. Direct health care expenses, including ambulatory visits, hospitalizations, and medications, are substantial, averaging $9,000 to $12,000 per person annually in high-income regions. However, these estimates do not fully
-
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-13 David Fudman, Ryan A. McConnell, Christina Ha, Siddharth Singh
The therapeutic armamentarium for management of inflammatory bowel diseases has expanded dramatically in the last 5 years, with the introduction of several medications with different mechanisms of action. These include the oral small molecule drugs Janus kinase inhibitors (including upadacitinib approved for Crohn’s disease and ulcerative colitis [UC], and tofacitinib, approved for UC) and sphingosphine
-
Symptom Profile of Patients With Intestinal Methanogen Overgrowth: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-13 Sepideh Mehravar, Will Takakura, Jiajing Wang, Mark Pimentel, Jason Nasser, Ali Rezaie
Archaea constitute one of the main 3 domains of the tree of life, distinct from eukaryotes and bacteria. Excessive luminal loads of methanogenic archaea (intestinal methanogen overgrowth [IMO]) have been implicated in the pathophysiology of various diseases, including constipation. To elucidate the phenotypical presentation of IMO, we performed a systematic review and meta-analysis of the prevalence
-
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-12 Antonio Facciorusso, Daryl Ramai, Jahnvi Dhar, Jayanta Samanta, Saurabh Chandan, Paraskevas Gkolfakis, Stefano Francesco Crinò, Marcello Maida, Andrea Anderloni, Ivo Boskoski, Konstantinos Triantafyllou, Mario Dinis-Ribeiro, Cesare Hassan, Lorenzo Fuccio, Marianna Arvanitakis
Limited evidence exists regarding the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on upper endoscopy. Therefore, a meta-analysis was conducted to comprehensively review the available evidence on this subject. A systematic bibliographic search was carried out until May 2024. Pooled estimates were analyzed using a random-effects model, with results presented as odds ratio (OR) and
-
Perianal Fistulizing Crohn’s Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-10 Luke N. Hanna, Sulak Anandabaskaran, Nusrat Iqbal, Jeroen Geldof, Jean-Frédéric LeBlanc, Anders Dige, Lilli Lundby, Séverine Vermeire, André D’Hoore, Bram Verstockt, Gabriele Bislenghi, Danny De Looze, Triana Lobaton, Dirk Van de Putte, Antonino Spinelli, Michele Carvello, Silvio Danese, Christianne J. Buskens, Krisztina Gecse, Roel Hompes, Marte Becker, Jarmila van der Bilt, Wilhelmus Bemelman, Shaji
Perianal fistulation is a challenging phenotype of Crohn’s disease, with significant impact on quality of life. Historically, fistulae have been classified anatomically in relation to the sphincter complex, and management guidelines have been generalized, with lack of attention to the clinical heterogenicity seen. The recent ‘TOpClass classification system’ for perianal fistulizing Crohn’s disease
-
Generative Artificial Intelligence Tools in Gastroenterology Training Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-06 Tasnim Ahmed, Loren G. Rabinowitz, Adam Rodman, Tyler M. Berzin
-
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of Art Update Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Silvia Sookoian, Yaron Rotman, Luca Valenti
Recent advances in the genetics of metabolic dysfunction-associated steatotic liver disease (MASLD) are gradually revealing the mechanisms underlying the heterogeneity of the disease and have shown promising results in patient stratification. Genetic characterization of the disease has been rapidly developed using genome-wide association studies, exome-wide association studies, phenome-wide association
-
Prevalence of Endoscopically Curable Low-Risk Cancer Among Large (≥20 mm) Nonpedunculated Polyps in the Right Colon Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Julia L. Gauci, Anthony Whitfield, Renato Medas, Clarence Kerrison, Francesco Vito Mandarino, David Gibson, Timothy O’Sullivan, Oliver Cronin, Sunil Gupta, Brian Lam, Varan Perananthan, Luke Hourigan, Simon Zanati, Rajvinder Singh, Spiro Raftopoulos, Alan Moss, Gregor Brown, Amir Klein, Lobke Desomer, David J. Tate, Steven J. Williams, Eric Y. Lee, Nicholas Burgess, Michael J. Bourke
Endoscopic submucosal dissection is increasingly promoted for the treatment of all large nonpedunculated colorectal polyps (LNPCPs) to cure potential low-risk cancers (superficial submucosal invasion without additional high-risk histopathologic features). The effect of a universal en bloc strategy on oncologic outcomes for the treatment of LNPCPs in the right colon is unknown. We evaluated this in
-
Double Wire Cannulation and Mechanical Lithotripsy in Billroth II With Therapeutic Gastroscope Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Grace E. Kim, Uzma D. Siddiqui
-
Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Sung Won Chung, Hyun Jun Um, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
Whether tenofovir or entecavir has different effects on the prevention of hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC) in secondary and tertiary preventive settings is still a matter of debate. This study aimed to compare the long-term prognosis of HCC between tenofovir and entecavir in patients with chronic hepatitis B. Chronic hepatitis B patients diagnosed with HCC between November
-
Proton Pump Inhibitors Are Recommended for Patients on Dual Antiplatelet Agents and Also for Patients on Anticoagulant Plus Aspirin Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Marvin Chinitz
-
Trainee Participation and Outcomes in High-risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the Stent Versus Indomethacin Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Sachin Wani, Jingwen Zhang, Lydia D. Foster, Valerie Durkalski-Mauldin, B. Joseph Elmunzer, Stent Versus Indomethacin (SVI) Study Group, Jose Serrano, Gregory A. Coté, Steven A. Edmundowicz, Raj Shah, Ji Young Bang, Shyam Varadarajulu, Vikesh K. Singh, Mouen Khashab, Richard S. Kwon, James M. Scheiman, Field F. Willingham, Steven A. Keilin, Georgios I. Papachristou, Amitabh Chak, Adam Slivka, Daniel
-
Biomarkers for Prediction of Alcohol-Related Liver Cirrhosis: A General Population–Based Swedish Study of 537,250 Individuals Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Gustav Jakobsson, Mats Talbäck, Niklas Hammar, Ying Shang, Hannes Hagström
The study sought to examine which biomarkers have the best predictive capabilities for future alcohol-related liver cirrhosis (ARLC) in a general population setting. This population-based cohort study includes approximately 35% of the inhabitants of Stockholm County who had left a blood sample at an outpatient visit in primary care or occupational health screening from 1985 to 1996. All subjects with
-
Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Kenneth Ernest-Suarez, Luis E. Murguía-Favela, Cora Constantinescu, Tiffany Fitzpatrick, Karina A. Top, Jia Hu, Taj Jadavji, Yvette Leung, Melissa Chan, Remo Panaccione, Cynthia H. Seow
Biologic therapies in the context of inflammatory bowel disease and pregnancy lead to improved maternal and fetal outcomes. Placental transfer results in detectable drug concentrations in infants. Rotavirus infection results in diarrheal related hospitalizations; however, the live oral vaccine is not currently recommended in biologic exposed infants. The aim of this study was to assess the effect of
-
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Fernando Magro, Laurent Peyrin-Biroulet, Bruce E. Sands, Silvio Danese, Vipul Jairath, Martina Goetsch, Abhishek Bhattacharjee, Joseph Wu, Diogo Branquinho, Irene Modesto, Brian G. Feagan
Histologic remission, a potentially important treatment target in ulcerative colitis (UC), is associated with favorable long-term outcomes. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active UC. This post-hoc analysis of the ELEVATE UC program evaluated the efficacy of etrasimod according to histologic and
-
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-30 Neehar D. Parikh, Patricia Jones, Reena Salgia, Irun Bhan, Lauren T. Grinspan, Janice H. Jou, Kali Zhou, Prasun Jalal, Giorgio Roccaro, Amol S. Rangnekar, Jihane N. Benhammou, Anjana Pillai, Neil Mehta, Joel Wedd, Ju Dong Yang, Amy K. Kim, Andres Duarte-Rojo, Omobonike O. Oloruntoba, Amit Tevar, Jennifer S. Au, Yamile Blain, Sanjana Rao, Onofrio A. Catalano, Sara Lewis, Mishal Mendiratta-Lala, Kevin
Noninvasive variceal risk stratification systems have not been validated in patients with hepatocellular carcinoma (HCC), which presents logistical barriers for patients in the setting of systemic HCC therapy. We aimed to develop and validate a noninvasive algorithm for the prediction of varices in patients with unresectable HCC. We performed a retrospective cohort study in 21 centers in the United
-
Baseline and Dynamic MAF-5 Score to Predict Liver Fibrosis and Liver-Related Events in General Population With MASLD Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-30 Shanghao Liu, Xuanwei Jiang, Junliang Fu, Vincent Wai-Sun Wong, Victor W. Zhong, Xiaolong Qi